01—Abstract
Summary
Summary of the 8-K filed October 28, 2024. Cited figures are marked; the original filing is the authoritative source.
Roivant Sciences Ltd. (ROIV) reported that the previously announced acquisition of its subsidiary Dermavant Sciences Ltd. by Organon & Co. closed on October 28, 2024.
Under the Merger Agreement dated September 17, 2024, Organon Bermuda Ltd., an indirect wholly owned subsidiary of Organon, merged into Dermavant, which continues as the surviving company and a wholly owned subsidiary of Organon. Roivant acted as representative of Dermavant's securityholders under the agreement. In connection with the closing, Dermavant repaid all amounts outstanding under its Credit Agreement dated May 14, 2021 (amended May 24, 2024), including accrued interest, premiums and exit fees, and the Credit Agreement was terminated in accordance with its terms.
The filing also furnishes a joint Organon and Roivant press release announcing the closing, which highlights VTAMA (tapinarof) cream, 1%a, approved by the FDA for plaque psoriasis, with an sNDA for atopic dermatitis under FDA review and PDUFA action expected in the fourth quarter of calendar 2024. The filing does not state the purchase price or other deal economics. The press release refers to Roivant continuing to share in the success of VTAMA, and it notes that Organon's prior announcement summarized the transaction terms.
02—Key points
Key Highlights
- Closing of the Dermavant acquisition by Organon on October 28, 2024; Dermavant is now a wholly owned subsidiary of Organon.
- Dermavant repaid all outstanding amounts under its Credit Agreement, including accrued interest, premiums and exit fees, and the agreement was terminated.
- VTAMA (tapinarof) cream, 1% is FDA-approved for plaque psoriasis in adults; an sNDA for atopic dermatitis is under FDA review with PDUFA action expected in Q4 calendar 2024.
- Roivant's management described the deal as a win-win outcome and said Roivant expects to continue sharing in the success of VTAMA.
- Roivant acted as representative of Dermavant's securityholders under the Merger Agreement dated September 17, 2024.
- The press release was furnished under Item 7.01 and is not deemed filed for Section 18 purposes.
03—Questions
Frequently Asked Questions
What did Roivant announce in this 8-K?
Roivant reported that its subsidiary Dermavant Sciences Ltd. was acquired by Organon & Co. through a merger completed on October 28, 2024, with Dermavant continuing as a wholly owned subsidiary of Organon.
What happened to Dermavant's debt?
As contemplated by the Merger Agreement, Dermavant repaid all amounts outstanding or payable under its Credit Agreement, including accrued interest, premiums and exit fees, and the Credit Agreement was terminated.
What is VTAMA and what regulatory steps are pending?
VTAMA (tapinarof) cream, 1% is a non-steroidal topical therapy approved by the FDA for plaque psoriasis in adults. The FDA is reviewing an sNDA for treatment of atopic dermatitis, with PDUFA action expected in the fourth quarter of calendar 2024.
Does the filing disclose the purchase price?
No. The filing refers to the Merger Agreement and the press release, and the press release states that a prior announcement by Organon summarized the transaction terms. The filing itself does not state the deal consideration.
What is Roivant's continuing interest in VTAMA?
In the joint press release, Roivant's President and Chief Investment Officer, Mayukh Sukhatme, MD, said Roivant is excited to continue to share meaningfully in the success of VTAMA along the way.
04—Continue